On this page
Betamethasone Dipropionate
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 071467-001 | BETAMETHASONE DIPROPIONATE | LOTION | BETAMETHASONE DIPROPIONATE | Prescription | AB |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 10 | Labeling | Approved | January 14, 2003 | — |
| Supplement | 9 | Manufacturing (CMC) | Approved | August 30, 2001 | — |
| Supplement | 8 | Manufacturing (CMC) | Approved | July 7, 2000 | — |
| Supplement | 7 | Manufacturing (CMC) | Approved | January 12, 2000 | — |
| Supplement | 6 | Manufacturing (CMC) | Approved | September 5, 1996 | — |
| Supplement | 5 | Manufacturing (CMC) | Approved | September 5, 1996 | — |
| Supplement | 4 | Manufacturing (CMC) | Approved | September 5, 1996 | — |
| Supplement | 3 | Manufacturing (CMC) | Approved | June 30, 1993 | — |
| Supplement | 2 | Manufacturing (CMC) | Approved | April 1, 1993 | — |
| Supplement | 1 | Manufacturing (CMC) | Approved | July 13, 1989 | — |
| Original application | 1 | Approved | August 10, 1987 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20221115). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Betamethasone Dipropionate Lotion USP, 0.05% is a medium-potency corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years and older.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION: Apply a few drops of Betamethasone Dipropionate Lotion to the affected skin areas and massage lightly until it disappears. Apply twice daily, in the morning and at night. If an infection develops, appropriate antimicrobial therapy should be instituted. Betamethasone Dipropionate products should not be used with occlusive dressings.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Betamethasone Dipropionate Lotion USP, 0.05% is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in these preparations.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The following local adverse reactions are reported infrequently when betamethasone dipropionate lotion 0.05% is used as recommended in the DOSAGE AND ADMINISTRATION section. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria. Adverse reactions reported to be possibly or probably related to treatment with betamethasone dipropionate lotion 0.05% during a pediatric study include: paresthesia (burning), erythema, erythematous rash, and dry skin. These adverse reactions each occurred in a different patient; 4% of the 25 patient population, respectively. An adverse reaction reported to be possibly or probably related to treatment in 2 different patients, 8%, of the 25 patients is puritis. Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.
Description
openFDA Drug LabelingDESCRIPTION Betamethasone Dipropionate Lotion USP, 0.05% contains betamethasone dipropionate, USP, a synthetic adrenocorticosteroid, for dermatologic use. Betamethasone, an analog of prednisolone, has high corticosteroid activity and slight mineralocorticoid activity. Betamethasone dipropionate is the 17, 21-dipropionate ester of betamethasone. Chemically, betamethasone dipropionate is 9-fluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate, with the empirical formula C 28 H 37 FO 7 , a molecular weight of 504.6, and the following structural formula: Betamethasone dipropionate is a white to creamy white, odorless crystalline powder, insoluble in water. Each gram of Betamethasone Dipropionate Lotion USP, 0.05% contains 0.64 mg betamethasone dipropionate (equivalent to 0.5 mg betamethasone) in a lotion base of carbomer homopolymer type B, isopropyl alcohol, and purified water. Sodium hydroxide is used to adjust pH. Image 1
Overdosage
openFDA Drug LabelingOVERDOSAGE: Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS ).
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED: Betamethasone Dipropionate Lotion, USP 0.05% is supplied as follows: 60 mL bottles (NDC 0713-0807-53) Shake well before using. Store at 25°C, excursions permitted between 15° and 30°C. Protect from light and freezing. Distributed by: Cosette Pharmaceuticals, Inc. South Plainfield, NJ 07080 Iss. 03/2021 8-0807CPLNC1 VC7520
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: BETAMETHASONE DIPROPIONATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 0713-0807-53 | 0713-0807 | Cosette Pharmaceuticals, Inc. | 1 BOTTLE in 1 CARTON (0713-0807-53) / 60 mL in 1 BOTTLE | September 5, 2016 |
| 0168-0057-60 | 0168-0057 | E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC | 1 BOTTLE in 1 CARTON (0168-0057-60) / 60 mL in 1 BOTTLE | August 12, 1985 |
| 45802-021-46 | 45802-021 | Padagis Israel Pharmaceuticals Ltd | 56.2 g in 1 BOTTLE, PLASTIC (45802-021-46) | June 30, 2006 |
| 0713-0807 | 0713-0807 | Cosette Pharmaceuticals, Inc. | — | September 5, 2016 |
| 0168-0057 | 0168-0057 | E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC | — | August 12, 1985 |
| 45802-021 | 45802-021 | Padagis Israel Pharmaceuticals Ltd | — | June 30, 2006 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.